Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

Five Under 5: Top Oncology Videos for the Week of 7/20

July 27th 2025

The top 5 OncLive videos of the week cover insights in multiple myeloma, breast cancer, melanoma, and CLL/SLL.

The OncFive: Top Oncology Articles for the Week of 7/20

July 26th 2025

RP1 BLA in advanced melanoma receives CRL from FDA, generic ibrutinib tablets gets green light for B-cell malignancies, and more.

SCIB1/iSCIB1+ Vaccines Plus Checkpoint Inhibition Generate Immune Responses in Advanced Melanoma

July 22nd 2025

Among patients with advanced melanoma and the target HLA type—representing 80% of the study population—treatment with iSCIB1+ yielded an ORR of 69%.

FDA Issues CRL for RP1 Plus Nivolumab for Advanced Melanoma

July 22nd 2025

The FDA has issued a complete response letter for RP1 plus nivolumab for advanced melanoma after a PD-1 inhibitor–containing regimen.

Dr Rutkowski on JPB898 With Ipilimumab in Stage III or Metastatic Stage IV Melanoma

July 22nd 2025

Piotr Rutkowski, MD, discusses a trial evaluating the nivolumab biosimilar JPB898 plus ipilimumab in stage III or metastatic stage IV melanoma.

Five Under 5: Top Oncology Videos for the Week of 7/13

July 20th 2025

The top 5 OncLive videos of the week cover insights in ovarian cancer, RCC, melanoma, non–small cell lung cancer, and non–muscle-invasive bladder cancer.

Sarilumab Plus Ipilimumab, Nivolumab, and Relatlimab Displays High Response Rate in Unresectable Melanoma

July 15th 2025

The combination of sarilumab, ipilimumab, nivolumab, and relatlimab displayed activity in patients with stage III or IV melanoma.

Five Under 5: Top Oncology Videos for the Week of 7/6

July 13th 2025

The top 5 OncLive videos of the week cover insights in ovarian cancer, RCC, melanoma, non–small cell lung cancer, and non–muscle-invasive bladder cancer.

Dr Mehnert on the Efficacy of Sarilumab Plus Ipilimumab, Nivolumab, and Relatlimab in Unresectable Melanoma

July 8th 2025

Janice M. Mehnert, MD, discusses the efficacy and safety profile of sarilumab plus ipilimumab, nivolumab, and relatimab in unresectable melanoma.

Emerging Immunotherapy Platforms Set to Redefine Melanoma Management Beyond the Frontline

July 3rd 2025

Douglas B. Johnson, MD, MSCI, discusses clinical questions, unmet needs, and exciting therapeutic developments with immuno-oncology in melanoma.

Dr Medina on the Long-Term Efficacy and Safety of Lifileucel TIL Therapy in Advanced Melanoma

July 3rd 2025

Theresa Medina, MD, discusses the long-term efficacy and safety of lifileucel TIL therapy in advanced melanoma.

Dr Tarhini on Neoadjuvant Pembrolizumab Plus Vidutolimod in Resectable Melanoma

July 2nd 2025

Ahmad A. Tarhini, MD, PhD, discusses findings from the ECOG-ACRIN EA6194 trial of pembrolizumab plus vidutolimod in resectable melanoma.

Bocodepsin/Binimetinib Is Tolerable, Shows Combinatorial Activity in NRAS-Mutant Metastatic Melanoma

July 1st 2025

Phase 2 findings from NAUTILUS supported the potential combinatorial activity of binimetinib plus bocodepsin in NRAS-mutant melanoma.

Five Under 5: Top Oncology Videos for the Week of 6/22

June 29th 2025

The top 5 OncLive videos of the week cover insights in myelofibrosis, lung cancer, ovarian cancer, breast cancer, and melanoma.

Encorafenib/Binimetinib/Nivolumab Improves PFS in BRAF V600+ Melanoma with Symptomatic Brain Metastases

June 27th 2025

Encorafenib plus binimetinib and nivolumab improved PFS in BRAF V600–mutant melanoma with symptomatic brain metastases.

Non-Melanoma Skin Cancer: Deep Dive into Treatment Strategies for Cutaneous Squamous Cell Carcinoma

June 26th 2025

On June 2, 2025, a group of oncologists gathered for an in-person workshop at the 2025 Annual Meeting of the American Society of Clinical Oncology to discuss advances in cutaneous squamous cell carcinoma (cSCC) treatment. Moderated by Soo Park, MD, the session focused on adjuvant, high-risk neoadjuvant and metastatic treatment, including the use of immune checkpoint inhibitors (ICIs). Faculty reviewed clinical trial data, shared real-world experiences, and debated evolving treatment strategies.

Advances in Immunotherapy Necessitate Nuanced Understanding of Clinical Application Across Tumor Types

June 26th 2025

Douglas B. Johnson, MD, MSCI, discusses the importance of Cancer Immunotherapy Awareness Month and the utility of immunotherapy across tumor types.

Dr Johnson on Treatment Gaps With Immunotherapy in Melanoma

June 25th 2025

Douglas B. Johnson, MD, MSCI, highlighted avenues for improving immunotherapy use in melanoma during Cancer Immunotherapy Awareness Month.

Neoadjuvant Vidutolimod Plus Pembrolizumab Elicits Responses and Is Safe in Stage III Melanoma

June 25th 2025

Ahmad Tarhini, MD, PhD, discusses key findings from the EA6194 trial and how these data support the continued investigation of vidutolimod in melanoma.

The OncFive: Top Oncology Updates for the Week of 6/8

June 14th 2025

The FDA has approved new options in head and neck cancer, lung cancer, and bladder cancer—and more from OncLive this week.